Search clinical trials for: Comparator: Sitagliptin

Total 2775 results

Clinical Nutrition Research Center, Illinois Institute...

Completed

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance (GSE3)

Impaired Glucose Tolerance

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
David D'Alessio, M.D.
Merck Sharp & Dohme LLC

Completed

DPP4 Inhibition & Beta Cell Function

Healthy

United States
Merck Sharp & Dohme LLC

Completed

Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
AstraZeneca

Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (MEASURE-HF)

Heart Failure | Type 2 Diabetes Mellitus

United States, Thailand, Korea, Republic of, Russian Federation, Ukraine, Hungary, Bulgaria, Chile, Canada, Romania
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Type 2 Diabetes Mellitus
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
Merck Sharp & Dohme LLC

Completed

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Type 2 Diabetes Mellitus
AstraZeneca
Bristol-Myers Squibb

Completed

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

Type 2 Diabetes

Mexico, South Africa, Norway, Argentina, Belgium, Denmark, Sweden, France, Italy
Merck Sharp & Dohme LLC

Completed

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Type 2 Diabetes Mellitus (T2DM)
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Type 2 Diabetes Mellitus
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
University of Sao Paulo General Hospital
InCor Heart Institute

Completed

DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function

Platelet Aggregation During Acute Myocardial Infarction

Brazil
Merck Sharp & Dohme LLC

Completed

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Type 2 Diabetes Mellitus
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Lin Liao

Unknown

Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin

Type 2 Diabetes Mellitus

China
Shanghai Jiao Tong University School of Medicine

Unknown

Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Type 2 Diabetes

China
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Added-on to Insulin Study (0431-051)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
Lund University

Completed

DPP-4 Inhibition, Incretins and Islet Function (CODI24)

Type 2 Diabetes

Sweden
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Type 2 Diabetes Mellitus (T2DM)
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus

3

Subscribe